Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing throughout the treatment ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...
Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many ...
Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...
Children who have multiple food allergies (FAs) and allergies to milk and eggs are more likely to have early-onset atopic dermatitis (AD).
Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...
A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...
If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...
The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback